GOSS Gossamer Bio Inc
Company Analysis
Latest News
🟢 Gossamer Bio is trading 8% up on October 13, 2026 after Chardan initiated coverage with a Buy rating
Gossamer Bio is trading at $10.03, up 8.08%, after Chardan initiated coverage with a Buy rating and a $160 price target. - Chardan cites seralutinib’s FDA...
Chardan Slaps a $160 Target on a $10 Stock — Is Gossamer Bio a Hidden Gem or a Mirage Built on a Failed Trial?
Shares of Gossamer Bio jumped 11.5% in pre-market trading Monday after boutique investment bank Chardan initiated coverage with a Buy rating and an eye-popping...
🟢 Gossamer Bio is trading 11.52% up in pre-market after Chardan initiates coverage with a Buy rating
Gossamer Bio is trading 11.52% higher in pre-market at $10.35 after Chardan initiated coverage with a Buy rating and a $160 price target, citing seralutinib’s...
🔴 Gossamer Bio is trading 6.38% down; no clear catalyst identified
Gossamer Bio is trading 6.38% down at $9.25, with no clear company-specific catalyst identified. - Searches found no company-specific announcement or news on...
🔴 Gossamer Bio is trading 7.6% down on October 7, 2026, amid biotech-sector pressure
Gossamer Bio is trading at $9.96, down 7.61%, amid biotech-sector pressure. - No new company-specific announcement or direct catalyst was identified for the...
🔴 Gossamer Bio is trading 6.31% down in after-hours trading
Gossamer Bio is trading at $10.10, down -6.31%, with no clear company-specific catalyst identified for the October 6 after-hours decline. - Available search...
🟢 Gossamer Bio is trading 8% up in pre-market
Gossamer Bio is trading at $11.50, up 7.98% in pre-market, with no clear company-specific overnight catalyst identified. - Its latest prominent announcement...
🔴 Gossamer Bio is trading 6.1% down in pre-market
Gossamer Bio is trading 6.1% down at $10.00 in pre-market, with no clear company-specific overnight catalyst identified. - Shares declined 0.56% at the...
🟢 Gossamer Bio is trading 6.2% up in after-hours trading, with no clear company-specific catalyst identified
Gossamer Bio is trading $11.31, up 6.20%, with no clear company-specific announcement explaining the rise. - Regular-session close: $10.65; the provided price...
🔴 Gossamer Bio is trading 5.4% down — no clear company announcement explains the drop
Gossamer Bio is trading at $10.13, down 5.37%, with no reported company announcement explaining the October 5 decline. - An October 1 report noted divided...
🔴 Gossamer Bio is trading 7.1% down with no clear catalyst identified
Gossamer Bio is trading at $11.01, down 7.09%, with no clear company-specific catalyst identified for the decline. - The September 23 seralutinib FDA...
🟢 Gossamer Bio is trading 5.7% up — no clear company-specific catalyst identified
Gossamer Bio is trading at $12.24, up +5.70%, with no clear company-specific catalyst identified for the move. - No clear company-specific announcement or...
GOSS Regains Nasdaq Listing Compliance Following 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. announced it has regained compliance with the Nasdaq's minimum bid price requirement, resolving a potential delisting issue. The company...
🟢 Gossamer Bio is trading 6.86% up with no clear company-specific catalyst
Gossamer Bio is trading 6.86% higher at $11.69 on September 28, 2026, with no clear company-specific announcement identified to explain the gain. - Its latest...
🔴 Gossamer Bio is trading 5.3% down in after-hours trading as PROSERA missed its prespecified statistical threshold
Gossamer Bio is trading 5.3% down at $10.36 after-hours as investors reassess seralutinib after the PROSERA trial missed its prespecified statistical...
🔴 Gossamer Bio is trading 5.5% down today as FDA has yet to accept seralutinib filing
Gossamer Bio is trading 5.5% down now at $10.33 as investors reassess the September 23, 2026 FDA submission for seralutinib. - The application follows PROSERA...
🟢 Gossamer Bio is trading 5.6% up today after filing its first FDA New Drug Application
Gossamer Bio is trading at $11.61, up 5.60% after submitting its first FDA New Drug Application for seralutinib on September 23. - The application targets...
Gossamer Bio Submits First New Drug Application to FDA for Seralutinib
Gossamer Bio announced it has submitted its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its drug candidate,...
🔴 Gossamer Bio is trading 10.35% down today as rising oil prices renew inflation concerns
Gossamer Bio is trading 10.35% down at $10.48 on September 23, 2026, as rising crude prices renew inflation concerns and weigh on equity valuations. - U.S....
🔴 Gossamer Bio is trading 5.8% down today with no clear catalyst identified
Gossamer Bio is trading 5.8% down now at $11.01, and the cause remains unclear. - No clear company-specific announcement or catalyst dated September 23, 2026...